Last reviewed · How we verify
Sodium Bicarbonate Tablets
Sodium Bicarbonate Tablets is a Small molecule drug developed by University of Colorado, Denver. It is currently in Phase 1 development.
Sodium bicarbonate tablets are being studied in clinical trials for various conditions, including Acute Myeloid Leukemia, Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases, and Sickle Cell Anemia. The tablets are administered orally in a dose of 600 mg as part of the treatment regimen in these trials.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sodium Bicarbonate Tablets |
|---|---|
| Sponsor | University of Colorado, Denver |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Increase in antihypertensive therapy
- New Lower Extremity Edema
- Dialysis initiation
- Increase in diuretic therapy
- High serum bicarbonate level
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet (EARLY_PHASE1)
- Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients. (NA)
- Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD (PHASE2)
- Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD) (NA)
- Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD (PHASE2)
- Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets (PHASE4)
- Sympatholysis in Chronic Kidney Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Bicarbonate Tablets CI brief — competitive landscape report
- Sodium Bicarbonate Tablets updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI
Frequently asked questions about Sodium Bicarbonate Tablets
What is Sodium Bicarbonate Tablets?
Who makes Sodium Bicarbonate Tablets?
What development phase is Sodium Bicarbonate Tablets in?
What are the side effects of Sodium Bicarbonate Tablets?
Related
- Manufacturer: University of Colorado, Denver — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing